$149/month for lower doses (1.5mg, 4mg), $299/month for higher doses (9mg, 25mg) Non-GLP-1 Options: Contrave, metformin, and other FDA-approved oral weight management medications Included in the $99/month subscription: Face-to-face video visits with a provider of the patients choice, unlimited provider messaging, lab work, and close clinical supervision Insurance prior authorization assistance for medication coverage Access to the Sesame app for progress tracking and habit support Pricing and What Reviewers Say Sesames pricing model separates clinical subscription from medication, with the subscription covering all care infrastructure and medication billed separately: Subscription: $99/month (billed on a 28-day cycle) Cash-Pay Medication: Wegovy (semaglutide injectable): starts at $499/month without insurance Wegovy pill: $149/month for lower doses
Here's what scientists think is going on (NPR): "Many days I don't drink at all
There is variability across drugs [169,170,171,172]
In summary, while GLP-1 RAs hold substantial promise as dual-action agents addressing both metabolic dysfunction and neuropsychiatric symptoms, their integration into psychiatric care demands rigorous clinical trials, biomarker-guided stratification, and mechanistic validation
Although AOM liraglutide (Saxenda) has been approved for treatment of obesity in adolescents since late 2020 ( 5 ), the approval of AOM semaglutide (Wegovy) in December 2022 for treatment of obesity for adolescents prompted new excitement ( 6 )
[DOI] [PMC free article] [PubMed] [Google Scholar] 156.Lung B., Callan K., McLellan M., et al
